Unterehmen auf Watchlist setzen
Mynaric
ISIN: US62857X1019
WKN: A3C7GA
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Mynaric · ISIN: US62857X1019 · Business Wire (ID: 20241111414578)
12 November 2024 06:06PM

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Mynaric AG (MYNA) Investors


The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Mynaric AG (MYNA) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Mynaric AG (“Mynaric” or the “Company”) (NASDAQ: MYNA) securities between June 20, 2024 and October 7, 2024, inclusive (the “Class Period”). Mynaric investors have until December 30, 2024 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

On August 20, 2024, Mynaric disclosed that it “now expect[ed] full-year 2024 IFRS-15 revenue to range between EUR 16.0 million to EUR 24.0 million compared to previous guidance of a range between EUR 50.0 million to EUR 70.0 million,” citing “production delays of CONDOR Mk3 caused by lower than expected production yields and component supplier shortages of key components.” The Company also disclosed that it “now expects full-year 2024 operating loss to range between a loss of EUR 55.0 million to EUR 50.0 million compared to previous guidance of a range between a loss of EUR 40.0 million to EUR 30.0 million,” citing “the lower than expected revenue and higher than expected production costs due to lower yields.” Additionally, the Company also disclosed the voluntary departure of its Chief Financial Officer “for personal reasons.”

On this news, Mynaric’s stock price fell $2.32, or 55.9%, to close at $1.83 per share on August 20, 2024, thereby injuring investors.

Then, on August 26, 2024, Mynaric announced that its Supervisory Board “agreed to terminate in mutual consent the appointment of [the Company’s Chief Executive Officer] as chairman and member of the Management Board.”

On this news, Mynaric’s stock price fell $0.11, or 9.7%, to close at $1.02 per share on August 27, 2024.

Then, on October 8, 2024, Mynaric disclosed that it had received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market Inc. notifying the Company that it was “no longer in compliance with the Nasdaq continued listing criteria . . . due to its failure to maintain a minimum of $50 million in market value of listed securities,” and that “Mynaric does not meet the alternatives of total assets and total revenue for continued listing.”

On this news, Mynaric’s stock price fell $0.07, or 4.4%, to close at $1.53 per share on October 8, 2024, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) lower-than-expected production yields and component supplier shortages of key components were causing production delays for Mynaric’s CONDOR Mk3 product; (2) the foregoing issues were likely to have a material negative impact on the Company’s revenue growth and cause the Company to incur an operating loss; (3) as a result, Mynaric was unlikely to meet its own previously issued financial guidance for FY 2024; (4) accordingly, the Company’s business and/or financial prospects were overstated; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Mynaric securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
info@frankcruzlaw.com
www.frankcruzlaw.com

Visuelle Wertentwicklung / Kursverlauf · Mynaric
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2024
BusinessWire
Kontakt:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422